| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | CMO &EVP Dev &Med Affairs
1 company
Garg Pushkal is an EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC.. Recent SEC Form 4 filings include 0 buys and 107 sells.
Estimated insider holdings value: $6.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | ALNY Alnylam Pharmaceuticals, Inc. | EVP Chief R&D | Sell | 1,510 | $362.87 | $547,928.97 | -0.3% | -13.2% | - | |
| Oct 3, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | EVP Chief R&D | Sell | 5,959 | $451.76 | $2,692,061.89 | -1.5% | -12.3% | - | |
| Aug 19, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | EVP Chief R&D | Sell | 3,304 | $455.75 | $1,505,796.79 | -1.1% | +0.5% | - | |
| Mar 24, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sale+OE | 9,766 | $293.36 | $2,864,985.00 | -19.5% | +7.7% | +6.0% | |
| Mar 4, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 2,557 | $242.92 | $621,150.40 | -0.7% | +26.0% | +34.7% | |
| Feb 28, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sale+OE | 935 | $241.69 | $225,976.83 | -0.9% | +18.7% | +34.9% | |
| Feb 18, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 3,109 | $253.43 | $787,904.15 | -1.3% | +16.7% | +33.1% | |
| Jan 27, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sale+OE | 52,592 | $285.00 | $14,988,720.00 | -81.4% | -7.9% | +28.2% | |
| Dec 12, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 1,752 | $251.00 | $439,759.94 | -1.5% | -1.2% | +62.1% | |
| Nov 26, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 1,682 | $250.98 | $422,144.31 | -1.8% | -1.7% | +75.7% |